Wealth Science Advisors LLC Purchases New Position in AbbVie Inc. $ABBV

Wealth Science Advisors LLC purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 2,697 shares of the company’s stock, valued at approximately $616,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Diversified Trust Co lifted its stake in shares of AbbVie by 23.6% in the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after buying an additional 10,891 shares in the last quarter. Permanent Capital Management LP bought a new position in AbbVie in the third quarter worth approximately $720,000. Railway Pension Investments Ltd raised its position in AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after acquiring an additional 211,800 shares during the period. World Investment Advisors raised its position in AbbVie by 9.4% in the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after acquiring an additional 9,811 shares during the period. Finally, Public Sector Pension Investment Board raised its position in AbbVie by 17.0% in the third quarter. Public Sector Pension Investment Board now owns 1,044,690 shares of the company’s stock worth $241,888,000 after acquiring an additional 151,644 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $1.4 billion, 185‑acre pharmaceutical manufacturing campus in Durham, NC — its largest-ever single-site capital investment — which management says will add advanced, AI-enabled production capacity for immunology, neuroscience and oncology drugs and create hundreds of jobs; investors view this as a long-term capacity and supply-chain strengthening move. Read More.
• Positive Sentiment: Analyst sentiment turned more constructive: Canaccord initiated coverage with a Strong Buy / $262 price target, which supports upside expectations and likely helped buying interest after the campus announcement. Read More.
• Neutral Sentiment: AbbVie struck an exclusive licensing deal with Haisco to develop pain medicines (AbbVie will own development/manufacturing/commercial rights) — a potentially positive medium-term pipeline expansion, but impact depends on development milestones and commercialization timing. Read More.
• Neutral Sentiment: Investors are also watching upcoming Q1 earnings (Apr. 29) and consensus estimates; previews and models are circulating (Zacks and others) and could re-rate the name depending on results vs. guidance. Read More.
• Negative Sentiment: The FDA issued a Complete Response Letter (CRL) for AbbVie’s trenibotulinumtoxinE (TrenibotE) BLA, citing manufacturing-process concerns; the agency did not request new clinical studies but requires AbbVie to resolve manufacturing questions before approval — this delays a potential new product launch and creates near-term revenue uncertainty for the neurotoxin program. Read More.
• Negative Sentiment: Regulatory focus on manufacturing (FDA requests for additional information / manufacturing concerns highlighted in multiple reports) increases scrutiny on AbbVie’s production controls and could raise near-term remediation costs or timelines. AbbVie says it is well-positioned to address the FDA’s comments, but the issue tempers enthusiasm until resolved. Read More.

Insider Buying and Selling

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective for the company. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Piper Sandler decreased their target price on shares of AbbVie from $299.00 to $294.00 and set an “overweight” rating on the stock in a research report on Thursday. Evercore dropped their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $253.19.

AbbVie Stock Performance

NYSE:ABBV opened at $200.97 on Friday. AbbVie Inc. has a one year low of $176.11 and a one year high of $244.81. The firm has a market cap of $355.34 billion, a P/E ratio of 85.15, a P/E/G ratio of 0.72 and a beta of 0.38. The firm has a 50-day simple moving average of $217.33 and a 200-day simple moving average of $222.62.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts predict that AbbVie Inc. will post 14.22 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. AbbVie’s dividend payout ratio is presently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.